IVI in the Media
KNIH, IVI sign MOU on research cooperation
|Korea National Institute of Health and IVI sign MOU on research collaboration|
Seoul, July 20, 2012—The Korea National Institute of Health (KNIH, Director-General Dr. Cho Myeong-chan) and the International Vaccine Institute (IVI, Director-General Christian Loucq) exchanged a memorandum of understanding to expedite research and development of vaccines for public use at IVI headquarters on July 20.
The two organizations have jointly conducted a project to develop technology for long-term storage of vaccines, and will expand joint research and development, cooperation, and exchange.
According to the MOU, the two organizations will boost research cooperation in vaccine development, and strengthen and expand cooperation in diverse fields of interest, including:
The two sides will also cooperate in the following areas:
The two organizations expect strengthened cooperation between the two sides will generate synergistic effect in the field of vaccine R&D, and thus enable them to emerge as global centers of research, including in the development of next-generation vaccines.
KNIH is responsible for research on infectious diseases and chronic illnesses that require management by the state. The Institute is focusing on vaccines against smallpox, anthrax, avian influenza, and hand, foot and mouth disease.
Meanwhile, IVI is the first international organization headquartered in Korea, and is hosted by the Korean government. The Institute is endeavoring to combat infectious diseases through research and development, clinical trials of vaccines, and vaccine assistance programs for developing countries with support from the Korean government and the Bill and Melinda Gates Foundation, among others.
KNIH Director-General Dr. Cho Myeong-chan said, “We will step up research in the vaccine field by engaging in far-reaching exchange with IVI, in order to consolidate the foundation to protect the health and safety of the people from infectious diseases.”
IVI Director-General Dr. Christian Loucq added, “IVI is very pleased to collaborate with KNIH on vaccine research projects and training initiatives, which will mutually benefit the two organizations as well as Korea’s vaccine R&D. More importantly, this collaboration will ultimately contribute to improving the health and well-being of people in Korea and worldwide.”